Fuji Pharma
4554.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 | 2020-09 |
|---|---|---|---|---|---|---|
| Revenue | ¥47.5bn | ¥41.9bn | ¥37.4bn | ¥32.6bn | ¥31.9bn | ¥31.3bn |
| Operating income | ¥4.2bn | ¥3.4bn | ¥3.5bn | ¥3.5bn | ¥3.4bn | — |
| Ordinary income | ¥3.7bn | ¥4.0bn | ¥4.1bn | ¥3.4bn | ¥3.3bn | ¥2.8bn |
| Total assets | ¥85.7bn | ¥83.7bn | ¥80.0bn | ¥71.3bn | ¥62.1bn | ¥59.3bn |
| Net assets / equity | ¥42.6bn | ¥42.4bn | ¥39.0bn | ¥34.5bn | ¥32.6bn | ¥39.6bn |
| EPS (basic) | ¥100.5 | ¥238.94 | ¥128.27 | ¥102.1 | ¥95.1 | ¥64.7 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-10-01 → 2026-03-31 | Half-year | 67 figures · EDINET |
| 2024-10-01 → 2025-09-30 | Annual | 196 figures · EDINET |
| 2024-10-01 → 2025-03-31 | Half-year | 67 figures · EDINET |
| 2023-10-01 → 2024-09-30 | Annual | 196 figures · EDINET |
| 2023-10-01 → 2024-03-31 | Quarterly Q2 | 69 figures · EDINET |
| 2023-10-01 → 2023-12-31 | Quarterly Q1 | 43 figures · EDINET |
| 2022-10-01 → 2023-09-30 | Annual | 196 figures · EDINET |
| 2022-10-01 → 2023-06-30 | Quarterly Q3 | 45 figures · EDINET |
| 2022-10-01 → 2023-03-31 | Quarterly Q2Amended | 69 figures · EDINET |
| 2022-10-01 → 2023-03-31 | Quarterly Q2 | 69 figures · EDINET |
| 2022-10-01 → 2022-12-31 | Quarterly Q1 | 43 figures · EDINET |
| 2021-10-01 → 2022-09-30 | Annual | 196 figures · EDINET |
| 2021-10-01 → 2022-06-30 | Quarterly Q3 | 45 figures · EDINET |
22 more reports are still being processed.